Drug-Target Information
Drug Name Target Name Drug Type Target Type Source Drug MeSHID Interaction Score Drug Status Target Action
tarextumab notch-2 receptor NA Clinical trial target TTD , DGIDB Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Malignant neoplasm of pancreas[MeSHID:D010190]
Small cell carcinoma of lung[MeSHID:D055752]
Pancreatic carcinoma[MeSHID:C562463]		 31.83 phase 2 antibody
tarextumab notch-2 receptor NA Clinical trial target TTD , DGIDB Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Malignant neoplasm of pancreas[MeSHID:D010190]
Small cell carcinoma of lung[MeSHID:D055752]
Pancreatic carcinoma[MeSHID:C562463]		 31.83 phase 2 unknown
tarextumab notch-3 receptor NA Clinical trial target TTD , DGIDB Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Malignant neoplasm of pancreas[MeSHID:D010190]
Small cell carcinoma of lung[MeSHID:D055752]
Pancreatic carcinoma[MeSHID:C562463]		 63.65 phase 2 antibody
tarextumab notch-3 receptor NA Clinical trial target TTD , DGIDB Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Malignant neoplasm of pancreas[MeSHID:D010190]
Small cell carcinoma of lung[MeSHID:D055752]
Pancreatic carcinoma[MeSHID:C562463]		 63.65 phase 2 unknown
click here to return to the previous page